CDK4 and melanoma: In this study, we aimed to evaluate the anti-cancer efficacy of ArcA as a cyclin D1/CDK4 inhibitor in metastatic melanoma cells, specifically using highly metastatic derivatives that had metastasized to the lung and brain [16].